Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Ronen Arbel"'
Autor:
Ronen Arbel, Daniel A Goldstein, Roi Tschernichovsky, Talish Razi, Keren Filosof, Idan Menashe, Doron Netzer
Publikováno v:
BMJ Oncology, Vol 3, Iss 1 (2024)
Objective Healthcare overuse is a major challenge for healthcare systems and patients worldwide. Professional guidelines such as the ‘Choosing Wisely’ guidelines have attempted to reduce specific examples of overuse. We examined the use of survei
Externí odkaz:
https://doaj.org/article/9573f478771c4aae9026d325d72fb024
Autor:
Ronen Arbel, Abed N. Azab, Mansi Oberoi, Enis Aboalhasan, Artyom Star, Khaled Elhaj, Fouad Khalil, Hilmi Alnsasra
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background and aim:Heart failure with preserved ejection fraction (HFpEF) is associated with an increased risk of heart failure (HF) hospitalizations and cardiovascular death (CVD). Both dapagliflozin and sacubitril–valsartan have recently shown co
Externí odkaz:
https://doaj.org/article/5bd4dca853454dafb8589ab17b1cfb56
Autor:
Chris P Gale, Jianhua Wu, Ramesh Nadarajah, Ronen Arbel, J Campbell Cowan, Moti Haim, Doron Zahger, Talish Razi Benita, Lior Rokach
Publikováno v:
BMJ Open, Vol 13, Iss 12 (2023)
Introduction Atrial fibrillation (AF) is a major public health issue and there is rationale for the early diagnosis of AF before the first complication occurs. Previous AF screening research is limited by low yields of new cases and strokes prevented
Externí odkaz:
https://doaj.org/article/60c18396c887458a89f2c5049d350a83
Autor:
Chris P Gale, Jianhua Wu, Ramesh Nadarajah, Ronen Arbel, David Hogg, Yoko M Nakao, Campbel Cowan, Keerthenan Raveendra, Kazuhiro Nakao, Moti Haim, Doron Zahger
Publikováno v:
Open Heart, Vol 10, Iss 2 (2023)
Objective Risk-guided atrial fibrillation (AF) screening may be an opportunity to prevent adverse events in addition to stroke. We compared events rates for new diagnoses of cardio-renal-metabolic diseases and death in individuals identified at highe
Externí odkaz:
https://doaj.org/article/9f1a94cb5f654e0e82d543220fe056cf
Autor:
Hilmi Alnsasra, Gal Tsaban, Adam Solomon, Fouad Khalil, Enis Aboalhasan, Abed N. Azab, Joseph Azuri, Ariel Hammerman, Ronen Arbel
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background and Aim: Dapagliflozin and empagliflozin have demonstrated favorable clinical outcomes among patients with chronic kidney disease (CKD). However, their comparative monetary value for improving outcomes in CKD patients is unestablished. We
Externí odkaz:
https://doaj.org/article/f239e2acc26241b6ac06ddf616508645
Autor:
Ronen Arbel, Joseph Pliskin
Publikováno v:
Vaccines, Vol 10, Iss 8, p 1347 (2022)
Measures employed to combat COVID-19 included public lockdowns and vaccination campaigns. Israel’s extensive public health system produced data demonstrating the real-world results of these measures. Our objective was to evaluate the health and eco
Externí odkaz:
https://doaj.org/article/747ff6e5432b428c888d99d8a2dc8b6e
Publikováno v:
Obesity. 31:1510-1513
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b366be5d0ae28bb994bd2772cd4209a
https://doi.org/10.1002/oby.23752
https://doi.org/10.1002/oby.23752
Autor:
Hilmi Alnsasra, Gal Tsaban, Adam Solomon, Fouad Khalil, Enis Aboalhasan, Jean Marc Weinstein, Joseph Azuri, Ariel Hammerman, Ronen Arbel
Publikováno v:
American Journal of Cardiovascular Drugs. 23:323-328
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1285d3aabd02276ce58ad12aae0bda86
https://doi.org/10.1007/s40256-023-00578-5
https://doi.org/10.1007/s40256-023-00578-5
Autor:
Yael Wolff Sagy, Roy Zucker, Ariel Hammerman, Hila Markovits, Noa Gur Arieh, Wiessam Abu Ahmad, Erez Battat, Noga Ramot, Guy Carmeli, Avner Mark-Amir, Gal Wagner-Kolasko, Hadar Duskin-Bitan, Shlomit Yaron, Alon Peretz, Ronen Arbel, Gil Lavie, Doron Netzer
Publikováno v:
Nature Medicine. 29:748-752
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d140d20e23004886ec5c048c5f23f684
https://doi.org/10.1038/s41591-023-02229-3
https://doi.org/10.1038/s41591-023-02229-3
Autor:
Gal Tsaban, Hilmi Alnsasra, Aref El Nasasra, Amjad Abu-Salman, Ala Abu-Dogosh, Itay Weissberg, Yael Ben-Baruch Golan, Orit Barrett, Roi Westreich, Enis Aboalhasan, Joseph Azuri, Ariel Hammerman, Ronen Arbel
Publikováno v:
American Journal of Cardiovascular Drugs. 22:677-683
Introduction: Secondary prevention of cardiovascular events among patients with diagnosed cardiovascular disease and high ischemic risk poses a significant challenge in clinical practice. The combinations of aspirin with low dose (LD) Ticagrelor or L
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f6530def92750555b294288e0e6a77
https://doi.org/10.1007/s40256-022-00543-8
https://doi.org/10.1007/s40256-022-00543-8